ABOUT US

Passionate,

For You and Your Family's Health.

Explore

Prenetics is the leading genetic testing/digital health company in Southeast Asia.

We empower individuals with valuable health information. With a simple saliva sample, individuals can discover how their genes affect their diet, drug response, disease and cancer risk.

This information enables people to make health a choice, by living healthier and proactively preventing diseases.

Our Team

Management Team
Danny Yeung

Danny Yeung

Chief Executive Officer

Danny Yeung is the Chief Executive Officer of Prenetics and sets business strategies and vision. Prior to Prenetics, Danny led multiple investments in DNA Genetic testing companies as Founding Partner/Investor at SXE Ventures. Previously, Danny founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to Danny leaving Groupon in early 2014, Danny served as CEO of Groupon East Asia, having scaled the business to a size of over USD $130m annually, overseeing a staff of 350 and being highly profitable. Danny’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong's award-winning dessert chain Hui Lau Shan into USA. After exiting Hui Lau Shan, Danny successfully ventured into hospitality furniture and executed multi-million dollar projects with MGM City Center, City of Dreams Macau and Venetian. Danny is currently a Founding Partner at SXE Ventures, Board Member at Parabase Genomics, Limited Partner and Mentor for 500 Startups. Danny received his BS in MIS from the University of San Francisco. Danny’s life motto is “Play Hard, Work Harder”.

Dr. Lawrence Tzang, Ph.D.

Dr. Lawrence Tzang, Ph.D.

Co-Founder and Chief Scientific Officer

Dr. Tzang is the Co-Founder and Chief Scientific Officer of Prenetics. Dr. Tzang is recognized as a leader in DNA based Molecular Diagnostic Techniques. Dr. Tzang has over 15 years industry experience and has spear-headed the development of over 30 proprietary panels, including DNA Microarray and Microfluidic platforms which has been used in research and in clinical settings. Dr. Tzang is also a Founding Member of the Hong Kong Society for Behavioural and Neural Genetics. Dr. Tzang holds seven global patents/patent applications and has authored 30 scientific articles. Dr. Tzang received his Ph.D in Genetics from City University of Hong Kong.

Peter Wong

Peter Wong

Chief Technology Officer

Peter Wong, DPhil (Oxon), is the Chief Technology Officer of Prenetics and is responsible for driving technology vision and roadmap, and engineering delivery. Prior to Prenetics, Peter was the Head of Engineering at Travelex, where he led its first digital transformation and successfully delivered a brand new international money transfer service, Travelex Wire. Peter also led Travelex's B2B business, and launched its first international payment platform with the World Bank Group. Peter has experience across various industries including investment banking and eCommerce; and is a frequent speaker at technology events such as AWS Summit and at universities. Peter holds a Doctorate degree in Computer Science from the University of Oxford, and BSc and MSc degrees in Computer Science from the University of Warwick.

Dr. Senthil Sundaram, MD

Dr. Senthil Sundaram, MD

Chief Clinical Officer

Dr. Sundaram, MD, is the Chief Clinical Officer of Prenetics. Dr. Sundaram is highly recognised for his experience as a physician-scientist,having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases using cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram’s research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram’s research works have been funded by the National Institute of Health (NIH), USA. Dr. Sundaram also serves as a reviewer of different journals and NIH study sections.

Dr. Belinda Cheung, Ph.D.

Dr. Belinda Cheung, Ph.D.

Vice President (Research & Development)

Dr. Cheung serves as Vice President (Research & Development) and has been instrumental in the creation of the company’s proprietary assay platform. Dr. Cheung has over 13 years In-Vitro Diagnostic (IVD) industry experience in product development as well as clinical settings. Dr. Cheung managed over 18 M HKD grants, and was previously the Principal Researcher in a joint collaboration study between Hong Kong Government and a consortium of listed companies in the bio-tech space. Dr. Cheung holds 7 global patents /patent applications and has published 16 scientific articles. Dr. Cheung received her Ph.D in Biochemistry from The Hong Kong Polytechnic University.

Dr. Candy Li, Ph.D.

Dr. Candy Li, Ph.D.

Vice President (Operation)

Dr. Candy Li serves as Vice President (Operation). Dr. Li is responsible for leading and overseeing Prenetics laboratory operations that adhering to strict international standards. Dr. Li specializes in viral mutation and cancer diagnosis research through advanced biotechnologies, including different platforms of Next-Generation Sequencing (NGS), Real-Time PCR, DNA Cloning, and Protein Analysis. Dr. Li has published 11 scientific articles including European Journal of Cancer, FEBS Journal, Gene etc. Dr. Li received her Ph.D in Biomedical Sciences from the Chinese University of Hong Kong.

Dr. Wing Chan, Pharm.D., R.Ph.

Dr. Wing Chan, Pharm.D., R.Ph.

Chief Pharmacist

Dr. Chan serves as Chief Pharmacist and is passionate about the advancement of Pharmacogenomics throughout Asia. Dr. Chan has a wealth of experience in both research university settings as well as physical practice, having been a senior practicing pharmacist in the USA. Dr. Chan has been deeply involved with clinical and translational research with a focus on the study of pharmacogenomics and pharmacokinetics in hematopoietic stem cell transplant (HCST) pediatric patients. Dr. Chan is a strong advocate for the implementation of pharmacogenomics into clinical practice. Dr. Chan received her Doctor of Pharmacy and her B.S. in Chemical Engineering from the University of Minnesota.

Jennifer Aum

Jennifer Aum

VP of Growth

Jennifer Aum is the VP of Growth at Prenetics and is responsible for product strategy and roadmap. In her role, Jennifer harnesses the power of proprietary technologies and digital services to empower individuals and improve health. Previously, Jennifer served as the Founder of OM Health, an eco-product curation company. Jennifer has a background in private equity and investment banking. In her previous roles at Credit Suisse in New York and Singapore followed by Tiger Ventures in Hong Kong, she oversaw new business and product launches in addition to numerous multi-billion dollar capital markets and M&A transactions. Jennifer graduated from the University of Pennsylvania with a B.S. (Finance + Healthcare Management) from the Wharton School and a B.S.N. (Nursing) from the School of Nursing.

Chief Scientific Board
Prof. Michael M Yang, PhD

Prof. Michael M Yang, PhD

Head of Department of Biomedical Sciences; Chair Professor of Chemistry and Biomedical Sciences, City University of Hong Kong

Professor Yang is a co-founder of Prenetics (formerly named Multigene) as a spin-off from City University focusing on the development of molecular diagnostics for early detection of diseases. Professor Yang’s research interest focuses on the development of biochip technology and nanomedicine for basic research and clinical applications. Professor Yang has published over 200 peer-reviewed scientific papers and obtained 23 patents. He has delivered more than 160 invited lectures in international conferences and universities, and trained 24 PhD/M.Phil. students and numerous postdoctoral fellows in his laboratory. He holds honorary professorships in Zhejiang University and the Third Military Medical University. Professor Yang serves in the grant review boards of Hong Kong Government Health and Medical Research Fund and Innovation and Technology Fund. He has been awarded the Chunhui Scholar Award by the Ministry of Education in China in 2003, the K. C. Wong Foundation Award in 2004, the Shenzhen Science and Technology Innovation Award in 2006, and the Hong Kong Technological Achievement Grand Award in 2007. Professor Yang obtained his PhD from University of Toronto and postdoctoral training in the Scripps Research Institute in USA.

Prof. Stephen Tsui, PhD

Prof. Stephen Tsui, PhD

Head of Division of Genomics and Bioinformatics, The Chinese University of Hong Kong

Prof. Tsui Kwok Wing Stephen is currently a Professor in the School of Biomedical Sciences, the Head of Division of Genomics and Bioinformatics and the Director of Hong Kong Bioinformatics Centre of the Chinese University of Hong Kong (CUHK). In 1995, he received his PhD degree in Biochemistry at CUHK. He was then appointed as an Assistant Professor in the Biochemistry Department in 1997 and promoted to the full professorship in 2004. He was also a former member of the International HapMap Consortium and worked on the single nucleotide polymorphisms of human chromosome 3p. During the SARS outbreak in 2003, his team was one of the earliest teams that cracked the complete genome of the SARS-coronavirus. Totally, he has published more than 176scientific papers in international journals, including Nature, NEJM, Lancet, PNAS, Circulation, JACI and Genome Biology and two US patents. His major research interests are next generation sequencing, bioinformatics, human genetic diseases and molecular microbiology.

Prof. Brian Tomlinson

Prof. Brian Tomlinson

Adjunct Professor, Department of Medicine & Therapeutics; Former Head, Division of Clinical Pharmacology, Former Professor of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong; Honorary Consultant Physician, Prince of Wales Hospital, Hospital Authority; Honorary Consultant, Prince of Wales Hospital Poison Treatment Centre, Hong Kong

Prof. Tomlinson is currently Adjunct Professor and was formerly Chair Professor in the Department of Medicine and Therapeutics and Head of the Division of Clinical Pharmacology at the Chinese University of Hong Kong and honorary Consultant Physician at the Prince of Wales Hospital, Hong Kong. He trained in internal medicine and Clinical Pharmacology at the Middlesex Hospital Medical School and University College Hospital, London. He received his MD from the University of London and was awarded Fellowships from the Royal College of Physicians of London, the Royal College of Physicians of Edinburgh, the Royal College of Physicians and Surgeons of Glasgow and the Hong Kong Academy of Medicine. He also holds Fellowships of the American College of Physicians, the American College of Clinical Pharmacology, the Hong Kong College of Physicians and the Hong Kong College of Cardiology. His clinical and research interests include the clinical pharmacology, toxicology and pharmacogenetics of drugs, particularly in the cardiovascular field, and the pathogenesis and treatment of hyperlipidaemia, hypertension, the metabolic syndrome and diabetes. He has trained over 30 postgraduate students and is an author of over 350 publications and over 500 conference abstracts and has given numerous invited lectures. He is a reviewer for many journals and serves on several Editorial Boards and is President of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases and Secretary General of the Pacific Rim Association for Clinical Pharmacogenetics.

Dr. Andy Bhattacharjee, Ph.D.

Dr. Andy Bhattacharjee, Ph.D.

President & Chief Scientific Officer at Parabase Genomics

Dr. Andy Bhattacharjee has over 15+ years of experience in Genomics in premier institutions and industry. He has created new businesses, managed projects, developed NEW technologies and authored high-impact peer-reviewed publications. He was Senior Scientist & Strategic Collaborations Manager of Life Sciences Division at Agilent Technologies Inc. (previously Hewlett Packard) prior to Parabase Genomics. His development of a focused sequencing approach earned him and his team the 2008 Agilent Innovation Award for Genomics and contributed to creating Agilent as the technology leader in targeted sequencing products. This work is reflected in his multiple contributions to the development of Agilent’s SureSelect target enrichment assay platform, a standard in Exome Sequencing today. He was also an author (with academic collaborators) of a seminal article on use of Exome Sequencing in medical genomics (with academic collaborators) published in Nature. This work was recognized as Science magazines top biological innovation in 2010. As a post-doctoral fellow at Dana Farber Cancer Institute/Harvard Medical School he developed the first molecular lung cancer classification system. Dr. Bhattacharjee holds a Ph.D. in Molecular Biology from University of Minnesota, a Masters Degree from University of Saskatchewan and bachelor’s degree from Banaras Hindu University.

Medical Advisory Board
Dr. Jason P. Caplan, MD, FAPA, FAPM

Dr. Jason P. Caplan, MD, FAPA, FAPM

Professor & Chair of Psychiatry, Creighton University School of Medicine at St. Joseph's Hospital and Medical Center

Jason P. Caplan, MD, FAPM is the Chair of Psychiatry at St. Joseph’s Hospital and Medical Center. Dr. Caplan is board certified by the American Board of Psychiatry and Neurology in Psychiatry and Psychosomatic Medicine. Dr. Caplan’s expertise centers on the psychiatric care of the medically ill patient, particularly on the prevention and management of delirium. He has authored many journal articles and textbook chapters on various aspects of the practice of psychiatry in the medical hospital and serves on the editorial board of two major psychiatric journals. He has been named a Fellow of the Academy of Psychosomatic Medicine and is a member of the American Psychiatric Association, Association for Academic Psychiatry, and the American Neuropsychiatric Association. Dr. Caplan received his medical degree from the Creighton University School of Medicine. He completed his residency in psychiatry at the Harvard Longwood Psychiatry Residency Training Program and fellowship in psychosomatic medicine/consultation psychiatry at the Massachusetts General Hospital.

Dr. Ron Worthington, Ph.D.

Dr. Ron Worthington, Ph.D.

Professor of Pharmaceutical Science at Southern Illinois University at Edwardsville

Dr. Worthington is an acknowledged leader in the field of advanced pharmacogenomics and personalized medicine. As a scientist at WUSTL, Dr. Worthington was part of the Genome Sequencing Center and had notably worked on the Human Genome Project that was completed in 2003. Dr. Worthington was also instrumental with his work at INSERM in Villejuif, France, helping clone the human CD9 gene. Dr. Worthington’s past work also included being Acquisitions Editor at Mosby, where he published the first edition of the genetics textbook by Nobel Prize Winner Leland Hartwell. In 2005, Dr. Worthington joined the faculty at the new school of pharmacy at Southern Illinois University Edwardsville (SIUE), where he developed the pharmacogenomics and biochemistry curriculum. Dr. Worthington is a committee member of the US National Association of Boards of Pharmacy. Dr. Worthington received his A.B. and Ph.D from Washington University in St. Louis.

Dr. Deepak Voora, MD

Dr. Deepak Voora, MD

Assistant Professor of Medicine, Department of Medicine, Duke University School of Medicine

Deepak Voora is a highly motivated physician-scientist with a long-standing interest in cardiovascular pharmacogenomics research. Since 2005, initially under the mentorship of Brian Gage, MD, then subsequently as a post-doctoral fellow under mentorship of Geoffrey Ginsburg, MD, PhD, and then as a faculty member. He has been focused on the area of cardiovascular pharmacogenomics that spans from discovery to translation into the clinic. Over the time his research has expanded from identifying single genetic variants to describe drug response to a broad “systems pharmacology” approach that studies the in vivo response to cardiovascular drugs in human subjects.

Dr. Jane E. Caplan, MD

Dr. Jane E. Caplan, MD

Child Psychiatrist, Scottsdale, AZ

Dr. Jane E. Caplan, MD is an ADHD and Child Psychiatry specialist located in Phoenix, Arizona. Dr. Caplan received her medical degree from the Creighton University School of Medicine in 2001. She was a Resident in Psychiatry at Harvard Longwood Psychiatry Residency Training Program and fellowship in Child and Adolescent Psychiatry at the Massachusetts General Hospital. Dr. Caplan is currently in private practice in Phoenix, Arizona where she specializes in patients with ADHD. She is a regular lecturer on managing ADHD in school aged children.

Dr. John Francis Peppin, DO, FACP

Dr. John Francis Peppin, DO, FACP

Clinical Adjunct Professor, College of Osteopathic Medicine, Marian University

Dr. Peppin is board certified in Internal Medicine and pain medicine and is a certified EPEC trainer. Elected Fellow of the American College of Physicians, a Kentucky Colonel in 2009 and PainWeek 2011 Clinician of the Year. He was formerly Medical Director, Global Pharmaceuticals, Mallinckrodt Pharmaceuticals in St. Louis; and Chief Medical Officer for Castle Medical in Atlanta Georgia. He has published over 65 articles in the fields of pain management, palliative care and bioethics and edited books and given numerous lectures, papers and posters at conferences nationally and internationally. Former reviewer for multiple journals and the Cochrane PaPaS Group.

Commercial Advisory Board
Sandor Weyers

Sandor Weyers

Prudential Corporation Asia - Former Chief Capital Officer

Sandor has held various senior leadership positions in the insurance industry in a career that spans over twenty years. He has worked for large multinational organisations in South Africa, the United States, Mexico, Taiwan and currently Hong Kong. Sandor was most recently the Chief Capital Officer for Prudential Corporation Asia’s regional business. He joined Prudential in 2009 and established the regional Capital Management function, growing Asia cashflow to the Global Headquarters from £40m in 2009 to £400m in 2013. Sandor established PCA Re in 2012, Prudential’s reinsurance captive, and was Chief Executive since inception. Prior to joining Prudential he was Vice President, Corporate Strategy, for AIG’s Greater China operations. Sandor is a leading expert in the insurance industry with an extensive global network.

Samita Malik

Samita Malik

MetLife Asia - Former VP Health

Samita is a seasoned insurance executive with experience across North America, Europe and Asia. Most recently, she was responsible for the strategic growth of MetLife’s health business across Asia, a US$ 4bn portfolio with sales in excess of US$ 700M across 8 Asian markets. Previously, she held management positions with MetLife in both Hong Kong and New York. Prior to joining MetLife, Samita was a management consultant at Bain & Company and served several large multinational insurance clients. She started her insurance career at Anthem, Inc which is currently the largest health insurer in the US. Samita holds an MBA from The Wharton School at the University of Pennsylvania and an MA in Economics from the University of Virginia. She is extremely passionate about reshaping the health insurance industry around the needs of the customer and believes in the disruptive power of technology to help achieve that.

Andy A. Liu

Andy A. Liu

IMS Health Asia and China - Former President

Andy A. Liu is currently the Vice Chairman of HKBIO. Mr. Liu has previously served as President of Asia Pacific and China for IMS Health, a TPG private equity portfolio company focusing on big data healthcare that went IPO in 2014. Mr. Liu was responsible for managing the P&L and entire business in the region inclusive of 16 countries/region in Asia: China, Australia, India, South Korea, New Zealand, Hong Kong, Taiwan, Vietnam, Indonesia, Philippines, Thailand, Singapore, Malaysia, Bangladesh, Sri Lanka and Pakistan. Previously he has served as Head of Strategy & Business Development for IMS Health where he was responsible for leading all M&A, investments, acquisitions, joint ventures, due diligence, deal transactions and partnerships in the Asia Pacific region.

Rolf Steffen

Rolf Steffen

Zuellig Pharma - Former Chief Executive Officer, Healthcare

Mr Steffen has over twenty years of experience in senior leadership positions in the healthcare industry in Asia Pacific. He was most recently Chief Executive for Healthcare Services and Investments at Zuellig Pharma, a privately held healthcare services company with sales in excess of US$ 9bn and 11’000 employees. Mr Steffen joined Zuellig Pharma in 1993 and held management positions in Taiwan and the Philippines before his move to the Corporate Headquarters in Hong Kong in 2002 as Regional Director, responsible for the activities of the Group in the ASEAN countries, Taiwan and Hong Kong. As a leading expert in healthcare services, Mr Steffen has an extensive global industry network. He served on the Board of Overseers of the International Partnership for Innovative Healthcare Delivery, an organization catalysed by the World Economic Forum supporting innovators globally and connecting them to potential strategic partners and funders.

Shuhei Morofuji

Shuhei Morofuji

Has a private jet but chooses to fly economy

Mr Morofuji is currently the Founder and CEO of REAPRA Pte Ltd. He was previously the Founder and CEO of SMS Co Ltd for 11 years which is one of the largest healthcare information platforms in Asia. SMS is listed on the Tokyo Stock Exchange with a market capitalization of over $700m USD.

Danny Yeung

Danny Yeung

Chief Executive Officer

Danny Yeung is the Chief Executive Officer of Prenetics and sets business strategies and vision. Prior to Prenetics, Danny led multiple investments in DNA Genetic testing companies as Founding Partner/Investor at SXE Ventures. Previously, Danny founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to Danny leaving Groupon in early 2014, Danny served as CEO of Groupon East Asia, having scaled the business to a size of over USD $130m annually, overseeing a staff of 350 and being highly profitable. Danny’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong's award-winning dessert chain Hui Lau Shan into USA. After exiting Hui Lau Shan, Danny successfully ventured into hospitality furniture and executed multi-million dollar projects with MGM City Center, City of Dreams Macau and Venetian. Danny is currently a Founding Partner at SXE Ventures, Board Member at Parabase Genomics, Limited Partner and Mentor for 500 Startups. Danny received his BS in MIS from the University of San Francisco. Danny’s life motto is “Play Hard, Work Harder”.

Dr. Lawrence Tzang, Ph.D.

Dr. Lawrence Tzang, Ph.D.

Co-Founder and Chief Scientific Officer

Dr. Tzang is the Co-Founder and Chief Scientific Officer of Prenetics. Dr. Tzang is recognized as a leader in DNA based Molecular Diagnostic Techniques. Dr. Tzang has over 15 years industry experience and has spear-headed the development of over 30 proprietary panels, including DNA Microarray and Microfluidic platforms which has been used in research and in clinical settings. Dr. Tzang is also a Founding Member of the Hong Kong Society for Behavioural and Neural Genetics. Dr. Tzang holds seven global patents/patent applications and has authored 30 scientific articles. Dr. Tzang received his Ph.D in Genetics from City University of Hong Kong.

Peter Wong

Peter Wong

Chief Technology Officer

Peter Wong, DPhil (Oxon), is the Chief Technology Officer of Prenetics and is responsible for driving technology vision and roadmap, and engineering delivery. Prior to Prenetics, Peter was the Head of Engineering at Travelex, where he led its first digital transformation and successfully delivered a brand new international money transfer service, Travelex Wire. Peter also led Travelex's B2B business, and launched its first international payment platform with the World Bank Group. Peter has experience across various industries including investment banking and eCommerce; and is a frequent speaker at technology events such as AWS Summit and at universities. Peter holds a Doctorate degree in Computer Science from the University of Oxford, and BSc and MSc degrees in Computer Science from the University of Warwick.

Dr. Senthil Sundaram, MD

Dr. Senthil Sundaram, MD

Chief Clinical Officer

Dr. Sundaram, MD, is the Chief Clinical Officer of Prenetics. Dr. Sundaram is highly recognised for his experience as a physician-scientist,having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases using cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram’s research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram’s research works have been funded by the National Institute of Health (NIH), USA. Dr. Sundaram also serves as a reviewer of different journals and NIH study sections.

Dr. Belinda Cheung, Ph.D.

Dr. Belinda Cheung, Ph.D.

Vice President (Research & Development)

Dr. Cheung serves as Vice President (Research & Development) and has been instrumental in the creation of the company’s proprietary assay platform. Dr. Cheung has over 13 years In-Vitro Diagnostic (IVD) industry experience in product development as well as clinical settings. Dr. Cheung managed over 18 M HKD grants, and was previously the Principal Researcher in a joint collaboration study between Hong Kong Government and a consortium of listed companies in the bio-tech space. Dr. Cheung holds 7 global patents /patent applications and has published 16 scientific articles. Dr. Cheung received her Ph.D in Biochemistry from The Hong Kong Polytechnic University.

Dr. Candy Li, Ph.D.

Dr. Candy Li, Ph.D.

Vice President (Operation)

Dr. Candy Li serves as Vice President (Operation). Dr. Li is responsible for leading and overseeing Prenetics laboratory operations that adhering to strict international standards. Dr. Li specializes in viral mutation and cancer diagnosis research through advanced biotechnologies, including different platforms of Next-Generation Sequencing (NGS), Real-Time PCR, DNA Cloning, and Protein Analysis. Dr. Li has published 11 scientific articles including European Journal of Cancer, FEBS Journal, Gene etc. Dr. Li received her Ph.D in Biomedical Sciences from the Chinese University of Hong Kong.

Dr. Wing Chan, Pharm.D., R.Ph.

Dr. Wing Chan, Pharm.D., R.Ph.

Chief Pharmacist

Dr. Chan serves as Chief Pharmacist and is passionate about the advancement of Pharmacogenomics throughout Asia. Dr. Chan has a wealth of experience in both research university settings as well as physical practice, having been a senior practicing pharmacist in the USA. Dr. Chan has been deeply involved with clinical and translational research with a focus on the study of pharmacogenomics and pharmacokinetics in hematopoietic stem cell transplant (HCST) pediatric patients. Dr. Chan is a strong advocate for the implementation of pharmacogenomics into clinical practice. Dr. Chan received her Doctor of Pharmacy and her B.S. in Chemical Engineering from the University of Minnesota.

Jennifer Aum

Jennifer Aum

VP of Growth

Jennifer Aum is the VP of Growth at Prenetics and is responsible for product strategy and roadmap. In her role, Jennifer harnesses the power of proprietary technologies and digital services to empower individuals and improve health. Previously, Jennifer served as the Founder of OM Health, an eco-product curation company. Jennifer has a background in private equity and investment banking. In her previous roles at Credit Suisse in New York and Singapore followed by Tiger Ventures in Hong Kong, she oversaw new business and product launches in addition to numerous multi-billion dollar capital markets and M&A transactions. Jennifer graduated from the University of Pennsylvania with a B.S. (Finance + Healthcare Management) from the Wharton School and a B.S.N. (Nursing) from the School of Nursing.

Prof. Michael M Yang, PhD

Prof. Michael M Yang, PhD

Head of Department of Biomedical Sciences; Chair Professor of Chemistry and Biomedical Sciences, City University of Hong Kong

Professor Yang is a co-founder of Prenetics (formerly named Multigene) as a spin-off from City University focusing on the development of molecular diagnostics for early detection of diseases. Professor Yang’s research interest focuses on the development of biochip technology and nanomedicine for basic research and clinical applications. Professor Yang has published over 200 peer-reviewed scientific papers and obtained 23 patents. He has delivered more than 160 invited lectures in international conferences and universities, and trained 24 PhD/M.Phil. students and numerous postdoctoral fellows in his laboratory. He holds honorary professorships in Zhejiang University and the Third Military Medical University. Professor Yang serves in the grant review boards of Hong Kong Government Health and Medical Research Fund and Innovation and Technology Fund. He has been awarded the Chunhui Scholar Award by the Ministry of Education in China in 2003, the K. C. Wong Foundation Award in 2004, the Shenzhen Science and Technology Innovation Award in 2006, and the Hong Kong Technological Achievement Grand Award in 2007. Professor Yang obtained his PhD from University of Toronto and postdoctoral training in the Scripps Research Institute in USA.

Prof. Stephen Tsui, PhD

Prof. Stephen Tsui, PhD

Head of Division of Genomics and Bioinformatics, The Chinese University of Hong Kong

Prof. Tsui Kwok Wing Stephen is currently a Professor in the School of Biomedical Sciences, the Head of Division of Genomics and Bioinformatics and the Director of Hong Kong Bioinformatics Centre of the Chinese University of Hong Kong (CUHK). In 1995, he received his PhD degree in Biochemistry at CUHK. He was then appointed as an Assistant Professor in the Biochemistry Department in 1997 and promoted to the full professorship in 2004. He was also a former member of the International HapMap Consortium and worked on the single nucleotide polymorphisms of human chromosome 3p. During the SARS outbreak in 2003, his team was one of the earliest teams that cracked the complete genome of the SARS-coronavirus. Totally, he has published more than 176scientific papers in international journals, including Nature, NEJM, Lancet, PNAS, Circulation, JACI and Genome Biology and two US patents. His major research interests are next generation sequencing, bioinformatics, human genetic diseases and molecular microbiology.

Prof. Brian Tomlinson

Prof. Brian Tomlinson

Adjunct Professor, Department of Medicine & Therapeutics; Former Head, Division of Clinical Pharmacology, Former Professor of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong; Honorary Consultant Physician, Prince of Wales Hospital, Hospital Authority; Honorary Consultant, Prince of Wales Hospital Poison Treatment Centre, Hong Kong

Prof. Tomlinson is currently Adjunct Professor and was formerly Chair Professor in the Department of Medicine and Therapeutics and Head of the Division of Clinical Pharmacology at the Chinese University of Hong Kong and honorary Consultant Physician at the Prince of Wales Hospital, Hong Kong. He trained in internal medicine and Clinical Pharmacology at the Middlesex Hospital Medical School and University College Hospital, London. He received his MD from the University of London and was awarded Fellowships from the Royal College of Physicians of London, the Royal College of Physicians of Edinburgh, the Royal College of Physicians and Surgeons of Glasgow and the Hong Kong Academy of Medicine. He also holds Fellowships of the American College of Physicians, the American College of Clinical Pharmacology, the Hong Kong College of Physicians and the Hong Kong College of Cardiology. His clinical and research interests include the clinical pharmacology, toxicology and pharmacogenetics of drugs, particularly in the cardiovascular field, and the pathogenesis and treatment of hyperlipidaemia, hypertension, the metabolic syndrome and diabetes. He has trained over 30 postgraduate students and is an author of over 350 publications and over 500 conference abstracts and has given numerous invited lectures. He is a reviewer for many journals and serves on several Editorial Boards and is President of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases and Secretary General of the Pacific Rim Association for Clinical Pharmacogenetics.

Dr. Andy Bhattacharjee, Ph.D.

Dr. Andy Bhattacharjee, Ph.D.

President & Chief Scientific Officer at Parabase Genomics

Dr. Andy Bhattacharjee has over 15+ years of experience in Genomics in premier institutions and industry. He has created new businesses, managed projects, developed NEW technologies and authored high-impact peer-reviewed publications. He was Senior Scientist & Strategic Collaborations Manager of Life Sciences Division at Agilent Technologies Inc. (previously Hewlett Packard) prior to Parabase Genomics. His development of a focused sequencing approach earned him and his team the 2008 Agilent Innovation Award for Genomics and contributed to creating Agilent as the technology leader in targeted sequencing products. This work is reflected in his multiple contributions to the development of Agilent’s SureSelect target enrichment assay platform, a standard in Exome Sequencing today. He was also an author (with academic collaborators) of a seminal article on use of Exome Sequencing in medical genomics (with academic collaborators) published in Nature. This work was recognized as Science magazines top biological innovation in 2010. As a post-doctoral fellow at Dana Farber Cancer Institute/Harvard Medical School he developed the first molecular lung cancer classification system. Dr. Bhattacharjee holds a Ph.D. in Molecular Biology from University of Minnesota, a Masters Degree from University of Saskatchewan and bachelor’s degree from Banaras Hindu University.

Dr. Jason P. Caplan, MD, FAPA, FAPM

Dr. Jason P. Caplan, MD, FAPA, FAPM

Professor & Chair of Psychiatry, Creighton University School of Medicine at St. Joseph's Hospital and Medical Center

Jason P. Caplan, MD, FAPM is the Chair of Psychiatry at St. Joseph’s Hospital and Medical Center. Dr. Caplan is board certified by the American Board of Psychiatry and Neurology in Psychiatry and Psychosomatic Medicine. Dr. Caplan’s expertise centers on the psychiatric care of the medically ill patient, particularly on the prevention and management of delirium. He has authored many journal articles and textbook chapters on various aspects of the practice of psychiatry in the medical hospital and serves on the editorial board of two major psychiatric journals. He has been named a Fellow of the Academy of Psychosomatic Medicine and is a member of the American Psychiatric Association, Association for Academic Psychiatry, and the American Neuropsychiatric Association. Dr. Caplan received his medical degree from the Creighton University School of Medicine. He completed his residency in psychiatry at the Harvard Longwood Psychiatry Residency Training Program and fellowship in psychosomatic medicine/consultation psychiatry at the Massachusetts General Hospital.

Dr. Ron Worthington, Ph.D.

Dr. Ron Worthington, Ph.D.

Professor of Pharmaceutical Science at Southern Illinois University at Edwardsville

Dr. Worthington is an acknowledged leader in the field of advanced pharmacogenomics and personalized medicine. As a scientist at WUSTL, Dr. Worthington was part of the Genome Sequencing Center and had notably worked on the Human Genome Project that was completed in 2003. Dr. Worthington was also instrumental with his work at INSERM in Villejuif, France, helping clone the human CD9 gene. Dr. Worthington’s past work also included being Acquisitions Editor at Mosby, where he published the first edition of the genetics textbook by Nobel Prize Winner Leland Hartwell. In 2005, Dr. Worthington joined the faculty at the new school of pharmacy at Southern Illinois University Edwardsville (SIUE), where he developed the pharmacogenomics and biochemistry curriculum. Dr. Worthington is a committee member of the US National Association of Boards of Pharmacy. Dr. Worthington received his A.B. and Ph.D from Washington University in St. Louis.

Dr. Deepak Voora, MD

Dr. Deepak Voora, MD

Assistant Professor of Medicine, Department of Medicine, Duke University School of Medicine

Deepak Voora is a highly motivated physician-scientist with a long-standing interest in cardiovascular pharmacogenomics research. Since 2005, initially under the mentorship of Brian Gage, MD, then subsequently as a post-doctoral fellow under mentorship of Geoffrey Ginsburg, MD, PhD, and then as a faculty member. He has been focused on the area of cardiovascular pharmacogenomics that spans from discovery to translation into the clinic. Over the time his research has expanded from identifying single genetic variants to describe drug response to a broad “systems pharmacology” approach that studies the in vivo response to cardiovascular drugs in human subjects.

Dr. Jane E. Caplan, MD

Dr. Jane E. Caplan, MD

Child Psychiatrist, Scottsdale, AZ

Dr. Jane E. Caplan, MD is an ADHD and Child Psychiatry specialist located in Phoenix, Arizona. Dr. Caplan received her medical degree from the Creighton University School of Medicine in 2001. She was a Resident in Psychiatry at Harvard Longwood Psychiatry Residency Training Program and fellowship in Child and Adolescent Psychiatry at the Massachusetts General Hospital. Dr. Caplan is currently in private practice in Phoenix, Arizona where she specializes in patients with ADHD. She is a regular lecturer on managing ADHD in school aged children.

Dr. John Francis Peppin, DO, FACP

Dr. John Francis Peppin, DO, FACP

Clinical Adjunct Professor, College of Osteopathic Medicine, Marian University

Dr. Peppin is board certified in Internal Medicine and pain medicine and is a certified EPEC trainer. Elected Fellow of the American College of Physicians, a Kentucky Colonel in 2009 and PainWeek 2011 Clinician of the Year. He was formerly Medical Director, Global Pharmaceuticals, Mallinckrodt Pharmaceuticals in St. Louis; and Chief Medical Officer for Castle Medical in Atlanta Georgia. He has published over 65 articles in the fields of pain management, palliative care and bioethics and edited books and given numerous lectures, papers and posters at conferences nationally and internationally. Former reviewer for multiple journals and the Cochrane PaPaS Group.

Sandor Weyers

Sandor Weyers

Prudential Corporation Asia - Former Chief Capital Officer

Sandor has held various senior leadership positions in the insurance industry in a career that spans over twenty years. He has worked for large multinational organisations in South Africa, the United States, Mexico, Taiwan and currently Hong Kong. Sandor was most recently the Chief Capital Officer for Prudential Corporation Asia’s regional business. He joined Prudential in 2009 and established the regional Capital Management function, growing Asia cashflow to the Global Headquarters from £40m in 2009 to £400m in 2013. Sandor established PCA Re in 2012, Prudential’s reinsurance captive, and was Chief Executive since inception. Prior to joining Prudential he was Vice President, Corporate Strategy, for AIG’s Greater China operations. Sandor is a leading expert in the insurance industry with an extensive global network.

Samita Malik

Samita Malik

MetLife Asia - Former VP Health

Samita is a seasoned insurance executive with experience across North America, Europe and Asia. Most recently, she was responsible for the strategic growth of MetLife’s health business across Asia, a US$ 4bn portfolio with sales in excess of US$ 700M across 8 Asian markets. Previously, she held management positions with MetLife in both Hong Kong and New York. Prior to joining MetLife, Samita was a management consultant at Bain & Company and served several large multinational insurance clients. She started her insurance career at Anthem, Inc which is currently the largest health insurer in the US. Samita holds an MBA from The Wharton School at the University of Pennsylvania and an MA in Economics from the University of Virginia. She is extremely passionate about reshaping the health insurance industry around the needs of the customer and believes in the disruptive power of technology to help achieve that.

Andy A. Liu

Andy A. Liu

IMS Health Asia and China - Former President

Andy A. Liu is currently the Vice Chairman of HKBIO. Mr. Liu has previously served as President of Asia Pacific and China for IMS Health, a TPG private equity portfolio company focusing on big data healthcare that went IPO in 2014. Mr. Liu was responsible for managing the P&L and entire business in the region inclusive of 16 countries/region in Asia: China, Australia, India, South Korea, New Zealand, Hong Kong, Taiwan, Vietnam, Indonesia, Philippines, Thailand, Singapore, Malaysia, Bangladesh, Sri Lanka and Pakistan. Previously he has served as Head of Strategy & Business Development for IMS Health where he was responsible for leading all M&A, investments, acquisitions, joint ventures, due diligence, deal transactions and partnerships in the Asia Pacific region.

Rolf Steffen

Rolf Steffen

Zuellig Pharma - Former Chief Executive Officer, Healthcare

Mr Steffen has over twenty years of experience in senior leadership positions in the healthcare industry in Asia Pacific. He was most recently Chief Executive for Healthcare Services and Investments at Zuellig Pharma, a privately held healthcare services company with sales in excess of US$ 9bn and 11’000 employees. Mr Steffen joined Zuellig Pharma in 1993 and held management positions in Taiwan and the Philippines before his move to the Corporate Headquarters in Hong Kong in 2002 as Regional Director, responsible for the activities of the Group in the ASEAN countries, Taiwan and Hong Kong. As a leading expert in healthcare services, Mr Steffen has an extensive global industry network. He served on the Board of Overseers of the International Partnership for Innovative Healthcare Delivery, an organization catalysed by the World Economic Forum supporting innovators globally and connecting them to potential strategic partners and funders.

Shuhei Morofuji

Shuhei Morofuji

Has a private jet but chooses to fly economy

Mr Morofuji is currently the Founder and CEO of REAPRA Pte Ltd. He was previously the Founder and CEO of SMS Co Ltd for 11 years which is one of the largest healthcare information platforms in Asia. SMS is listed on the Tokyo Stock Exchange with a market capitalization of over $700m USD.